Phase II trial of AVN 322 in patients with Alzheimer's disease.
Phase of Trial: Phase II
Latest Information Update: 27 Jun 2013
At a glance
- Drugs AVN 322 (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Sponsors Avineuro Pharmaceuticals
- 27 Jun 2013 Status changed from planning to discontinued.
- 09 Feb 2010 New trial record